{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:42:07Z","timestamp":1774698127800,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004954","name":"Augustinus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danish Kidney Patient Organization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and hypothesis<\/jats:title>\n                  <jats:p>While the primary treatment for minimal change disease (MCD) is prednisolone, the immunosuppressive treatment at relapse is less well defined. More treatment options for MCD have become available and concerns about the adverse effects of prednisolone have been raised. It is unclear to what extent this has influenced the treatment of relapsing disease. Thus, the objective of this study is to characterize the changes in the immunosuppressive treatment of relapse in MCD over the past 35\u00a0years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre, retrospective cohort including adult patients with biopsy-proven MCD from 13 hospitals in Denmark and the Netherlands between 1985 and 2022. Patients were identified from pathology registers. Information on treatment and clinical outcomes was retrieved from health records. Treatment before and after 2010 was compared.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 239 patients with a median age of 46\u00a0years, 55% female and 64% being diagnosed before 2010. A first relapse was identified in 50% and a second relapse in 28%. The most frequently prescribed treatment at first relapse was prednisolone monotherapy before and after 2010 (67% and 44% of patients, respectively), while the use of calcineurin inhibitors (CNI) increased 3-fold after 2010 compared with before 2010. At second relapse CNI was the most frequently prescribed treatment after 2010, while the use of both cyclophosphamide and prednisolone decreased when compared with before 2010. A similar trend was observed at the 3rd to 14th relapse with CNI (44% of patients) and rituximab (35% of patients) being the most frequently prescribed treatments after 2010 while the use of cyclophosphamide and prednisolone decreased (0% and 21% of patients, respectively). Regardless of treatment, remission rates remained high.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The treatment of relapses in MCD has changed since 2010 with reduced use of prednisolone monotherapy and cyclophosphamide, and increased use of CNI and rituximab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf072","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:41:38Z","timestamp":1745541698000},"page":"1941-1948","source":"Crossref","is-referenced-by-count":1,"title":["Temporal trends in the treatment of relapsing minimal change podocytopathy\u2014a binational cohort study"],"prefix":"10.1093","volume":"40","author":[{"given":"Tilde","family":"Kristensen","sequence":"first","affiliation":[{"name":"Aarhus University Hospital Department of Renal Medicine, ,","place":["Denmark"]},{"name":"Aarhus University Department of Clinical Medicine, , Aarhus ,","place":["Denmark"]},{"name":"Regional Hospital Central Jutland Medical Diagnostic Center, University Clinic for Innovative Patient Pathways, , Viborg ,","place":["Denmark"]},{"name":"Radboud UMC Department of Renal Medicine, , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-4916","authenticated-orcid":false,"given":"Rutger","family":"Maas","sequence":"additional","affiliation":[{"name":"Radboud UMC Department of Renal Medicine, , Nijmegen ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3715-7266","authenticated-orcid":false,"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital Department of Renal Medicine, ,","place":["Denmark"]},{"name":"Aarhus University Department of Clinical Medicine, , Aarhus ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Ivarsen","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital Department of Renal Medicine, ,","place":["Denmark"]},{"name":"Aarhus University Department of Clinical Medicine, , Aarhus ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"2025092904572463300_bib1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092904572463300_bib2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2215\/CJN.01920219","article-title":"Management of adult minimal change disease","volume":"14","author":"Korbet","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092904572463300_bib3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2014application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int"},{"key":"2025092904572463300_bib4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ki.2012.412","article-title":"Therapy of relapsing minimal-change disease in adults: a new approach?","volume":"83","author":"Glassock","year":"2013","journal-title":"Kidney Int"},{"key":"2025092904572463300_bib5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ckj\/sfx035","article-title":"Efficacy of mycophenolate treatment in adults with steroid-dependent\/frequently relapsing idiopathic nephrotic syndrome","volume":"10","author":"Sandoval","year":"2017","journal-title":"Clin Kidney J"},{"key":"2025092904572463300_bib6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/ndt\/gfaa133","article-title":"Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease","volume":"36","author":"Heybeli","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"14","author":"Xue","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025092904572463300_bib8","first-page":"16","article-title":"The efficacy of rituximab in adult frequently relapsing minimal change disease","volume":"10","author":"King","year":"2017","journal-title":"Clin Kidney J"},{"key":"2025092904572463300_bib9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000360908","article-title":"Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review","volume":"39","author":"Kronbichler","year":"2014","journal-title":"Am J Nephrol"},{"key":"2025092904572463300_bib10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ndt\/gft312","article-title":"Rituximab for minimal change disease in adults: long-term follow-up","volume":"29","author":"Bruchfeld","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib11","first-page":"1326","article-title":"Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial","volume":"8","author":"Ponticelli","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.clinthera.2012.03.008","article-title":"Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial","volume":"34","author":"Li","year":"2012","journal-title":"Clin Ther"},{"key":"2025092904572463300_bib13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/ckj\/sfw028","article-title":"Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis","volume":"9","author":"Fernandez-Juarez","year":"2016","journal-title":"Clin Kidney J"},{"key":"2025092904572463300_bib14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ndt\/gfp422","article-title":"Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome","volume":"25","author":"Eguchi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","article-title":"The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a case series","volume":"69","author":"Maas","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2025092904572463300_bib16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1046\/j.1523-1755.1999.07002.x","article-title":"Management of minimal lesion glomerulonephritis: evidence-based recommendations","volume":"55","author":"Bargman","year":"1999","journal-title":"Kidney Int"},{"key":"2025092904572463300_bib17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2025092904572463300_bib18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jama.1955.02960060017005","article-title":"Major undesirable side-effects resulting from prednisolone and prednisone","volume":"158","author":"Bollet","year":"1955","journal-title":"JAMA"},{"key":"2025092904572463300_bib19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2025092904572463300_bib20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025092904572463300_bib21","first-page":"CD001431","article-title":"Decision aids for people facing health treatment or screening decisions","volume":"4","author":"Stacey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025092904572463300_bib22","doi-asserted-by":"publisher","first-page":"e0199228","DOI":"10.1371\/journal.pone.0199228","article-title":"Treatment patterns and steroid dose for adult minimal change disease relapses: a retrospective cohort study","volume":"13","author":"Ozeki","year":"2018","journal-title":"PLoS One"},{"key":"2025092904572463300_bib23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092904572463300_bib24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ckj\/sft063","article-title":"Minimal-change disease in adolescents and adults: epidemiology and therapeutic response","volume":"6","author":"Keskar","year":"2013","journal-title":"Clin Kidney J"},{"key":"2025092904572463300_bib25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10157-015-1216-x","article-title":"Evidence-based clinical practice guidelines for nephrotic syndrome 2014","volume":"20","author":"Nishi","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"2025092904572463300_bib26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/ndt\/gfg134","article-title":"Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses","volume":"18","author":"Tse","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/ki.1986.130","article-title":"Adult-onset minimal change nephrotic syndrome: a long-term follow-up","volume":"29","author":"Nolasco","year":"1986","journal-title":"Kidney Int"},{"key":"2025092904572463300_bib28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1053\/j.ajkd.2022.11.012","article-title":"Age of onset and disease course in biopsy-proven minimal change disease: an analysis from the cure glomerulonephropathy network","volume":"81","author":"Chen","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025092904572463300_bib29","doi-asserted-by":"publisher","first-page":"14771","DOI":"10.1038\/s41598-023-41909-5","article-title":"Demographics and treatment of patients with primary nephrotic syndrome in Japan using a national registry of clinical personal records","volume":"13","author":"Nakagawa","year":"2023","journal-title":"Sci Rep"},{"key":"2025092904572463300_bib30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2215\/CJN.12331213","article-title":"Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study","volume":"9","author":"Shinzawa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025092904572463300_bib31","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/ndt\/gft207","article-title":"Tacrolimus as rescue therapy for adult-onset refractory minimal change nephrotic syndrome with reversible acute renal failure","volume":"28","author":"Li","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2169\/internalmedicine.43.668","article-title":"Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome","volume":"43","author":"Matsumoto","year":"2004","journal-title":"Intern Med"},{"key":"2025092904572463300_bib33","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/ndt\/gfm637","article-title":"Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome","volume":"23","author":"Li","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025092904572463300_bib34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","article-title":"Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome","volume":"39","author":"Nakayama","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2025092904572463300_bib35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/j.ajkd.2014.09.022","article-title":"Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults","volume":"65","author":"Szeto","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2025092904572463300_bib36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.34067\/KID.0000000000000133","article-title":"Clinical course of adult FSGS and minimal change disease in North American and Japanese cohorts","volume":"4","author":"Ozeki","year":"2023","journal-title":"Kidney360"},{"key":"2025092904572463300_bib37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12882-018-0999-x","article-title":"Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes","volume":"19","author":"Fenton","year":"2018","journal-title":"BMC Nephrol"},{"key":"2025092904572463300_bib38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000046215","article-title":"Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis","volume":"21","author":"Huang","year":"2001","journal-title":"Am J Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf072\/63002925\/gfaf072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/10\/1941\/63002925\/gfaf072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/10\/1941\/63002925\/gfaf072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:57:32Z","timestamp":1759136252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/10\/1941\/8119395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,4,24]]},"published-print":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf072","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,4,24]]}}}